Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13831608 | 0.82 | NOTUM (0.50) | NOTUMALDH1A1NPSR1LMNASMN1; SMN2 | |
| SCHEMBL7674419 | 0.82 | NOTUM (0.50) | NOTUMALDH1A1NPSR1LMNASMN1; SMN2 | |
| SCHEMBL13831594 | 0.82 | NOTUM (0.50) | NOTUMALDH1A1NPSR1LMNASMN1; SMN2 | |
| SCHEMBL11348353 | 0.82 | NOTUM (0.47) | NOTUMALDH1A1NPSR1LMNASMN1; SMN2 | |
| SCHEMBL23084530 | 0.80 | ALDH1A1 (0.37) | ALDH1A1CYP2D6 | |
| SCHEMBL19235053 | 0.80 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL11354688 | 0.79 | NOTUM (0.47) | NOTUMALDH1A1NPSR1LMNASMN1; SMN2 | |
| SCHEMBL11346039 | 0.79 | NOTUM (0.51) | NOTUMALDH1A1NPSR1LMNASMN1; SMN2 | |
| SCHEMBL19120875 | 0.79 | NOTUM (0.47) | NOTUMALDH1A1NPSR1LMNASMN1; SMN2 | |
| SCHEMBL11351137 | 0.79 | NOTUM (0.47) | NOTUMALDH1A1NPSR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2704575-B1 | COMPOSITION FOR INHIBITION OF INSECT SENSING | UNIV VANDERBILT (US) | 2020-06-03 | — | — | EP | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | NOTUM 3081/4885ALDH1A1 1645/4885NPSR1 1306/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | NOTUM 2423/4885ALDH1A1 2531/4885NPSR1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.